|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Colombet M, Soerjomataram I,
Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the
global cancer incidence and mortality in 2018: GLOBOCAN sources and
methods. Int J Cancer. 144:1941–1953. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691. 2017.
View Article : Google Scholar
|
|
4
|
van der Pool AE, Damhuis RA, Ijzermans JN,
de Wilt JH, Eggermont AM, Kranse R and Verhoef C: Trends in
incidence, treatment and survival of patients with stage IV
colorectal cancer: A population-based series. Colorectal Dis.
14:56–61. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fakih MG: Metastatic colorectal cancer:
Current state and future directions. J Clin Oncol. 33:1809–1824.
2015. View Article : Google Scholar
|
|
6
|
Akagi K, Oki E, Taniguchi H, Nakatani K,
Aoki D, Kuwata T and Yoshino T: Real-world data on microsatellite
instability status in various unresectable or metastatic solid
tumors. Cancer Sci. 112:1105–1113. 2021. View Article : Google Scholar
|
|
7
|
Lumish MA and Cercek A: Immunotherapy for
the treatment of colorectal cancer. J Surg Oncol. 123:760–774.
2021. View Article : Google Scholar
|
|
8
|
André T, Shiu KK, Kim TW, Jensen BV,
Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs
P, et al: Pembrolizumab in microsatellite-instability-high advanced
colorectal cancer. N Engl J Med. 383:2207–2218. 2020. View Article : Google Scholar
|
|
9
|
Overman MJ, Lonardi S, Wong KYM, Lenz HJ,
Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill
A, et al: Durable clinical benefit with nivolumab plus ipilimumab
in DNA mismatch repair-deficient/microsatellite instability-high
metastatic colorectal cancer. J Clin Oncol. 36:773–779. 2018.
View Article : Google Scholar
|
|
10
|
Seymour MT and Morton D: FOxTROT: An
international randomised controlled trial in 1052 patients (pts)
evaluating neoadjuvant chemotherapy (NAC) for colon cancer. J Clin
Oncol. 37 (Suppl 15):S35042019. View Article : Google Scholar
|
|
11
|
Bassi C, Marchegiani G, Dervenis C, Sarr
M, Abu Hilal M, Adham M, Allen P, Andersson R, Asbun HJ, Besselink
MG, et al: The 2016 update of the International Study Group (ISGPS)
definition and grading of postoperative pancreatic fistula: 11
years after. Surgery. 161:584–591. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Krishnamoorthy M, Lenehan JG and Maleki
Vareki S: Neoadjuvant immunotherapy for high-risk, resectable
malignancies: Scientific rationale and clinical challenges. J Natl
Cancer Inst. 113:823–832. 2021. View Article : Google Scholar
|
|
13
|
Lee AY and Brady MS: Neoadjuvant
immunotherapy for melanoma. J Surg Oncol. 123:782–788. 2021.
View Article : Google Scholar
|
|
14
|
Cloughesy TF, Mochizuki AY, Orpilla JR,
Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA,
Sanders CM, et al: Neoadjuvant anti-PD-1 immunotherapy promotes a
survival benefit with intratumoral and systemic immune responses in
recurrent glioblastoma. Nat Med. 25:477–486. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jia XH, Xu H, Geng LY, Jiao M, Wang WJ,
Jiang LL and Guo H: Efficacy and safety of neoadjuvant
immunotherapy in resectable nonsmall cell lung cancer: A
meta-analysis. Lung Cancer. 147:143–153. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chalabi M, Fanchi LF, Dijkstra KK, Van den
Berg JG, Aalbers AG, Sikorska K, Lopez-Yurda M, Grootscholten C,
Beets GL, Snaebjornsson P, et al: Neoadjuvant immunotherapy leads
to pathological responses in MMR-proficient and MMR-deficient
early-stage colon cancers. Nat Med. 26:566–576. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kinney RE and Khalil M: Neoadjuvant
immunotherapy in microsatellite-instability high nonmetastatic
colorectal cancer: A single-institute experience and review of the
literature. Clin Colorectal Cancer. 20:e109–e112. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tomasello G, Petrelli F, Ghidini M, Russo
A, Passalacqua R and Barni S: FOLFOXIRI plus bevacizumab as
conversion therapy for patients with initially unresectable
metastatic colorectal cancer: A systematic review and pooled
analysis. JAMA Oncol. 3:e1702782017. View Article : Google Scholar
|
|
19
|
Gruenberger T, Bridgewater J, Chau I,
García Alfonso P, Rivoire M, Mudan S, Lasserre S, Hermann F,
Waterkamp D and Adam R: Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in
patients with initially unresectable liver metastases from
colorectal cancer: The OLIVIA multinational randomised phase II
trial. Ann Oncol. 26:702–708. 2015. View Article : Google Scholar
|
|
20
|
Hu H, Wang K, Huang M, Kang L, Wang W,
Wang H, Qiu M, Lin R, Zhang H, Lan P, et al: Modified FOLFOXIRI
with or without cetuximab as conversion therapy in patients with
RAS/BRAF wild-type unresectable liver metastases colorectal cancer:
The FOCULM multicenter phase II trial. Oncologist. 26:e90–e98.
2021. View Article : Google Scholar
|
|
21
|
Yang J, Bi F and Gou H: Complete
pathologic response after concurrent treatment with pembrolizumab
and radiotherapy in metastatic colorectal cancer: A case report.
Onco Targets Ther. 14:2555–2561. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Curran MA, Montalvo W, Yagita H and
Allison JP: PD-1 and CTLA-4 combination blockade expands
infiltrating T cells and reduces regulatory T and myeloid cells
within B16 melanoma tumors. Proc Natl Acad Sci USA. 107:4275–4280.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sharma P and Allison JP: The future of
immune checkpoint therapy. Science. 348:56–61. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Postow MA, Chesney J, Pavlick AC, Robert
C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK,
Agarwala SS, et al: Nivolumab and ipilimumab versus ipilimumab in
untreated melanoma. N Engl J Med. 372:2006–2017. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wolchok JD, Hoos A, O'Day S, Weber JS,
Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, et al:
Guidelines for the evaluation of immune therapy activity in solid
tumors: Immune-related response criteria. Clin Cancer Res.
15:7412–7420. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Colle R, Radzik A, Cohen R, Pellat A,
Lopez-Tabada D, Cachanado M, Duval A, Svrcek M, Menu Y and André T:
Pseudoprogression in patients treated with immune checkpoint
inhibitors for microsatellite instability-high/mismatch
repair-deficient metastatic colorectal cancer. Eur J Cancer.
144:9–16. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gerwing M, Herrmann K, Helfen A,
Schliemann C, Berdel WE, Eisenblätter M and Wildgruber M: The
beginning of the end for conventional RECIST-novel therapies
require novel imaging approaches. Nat Rev Clin Oncol. 16:442–458.
2019. View Article : Google Scholar
|
|
28
|
Kebir S, Rauschenbach L, Galldiks N,
Schlaak M, Hattingen E, Landsberg J, Bundschuh RA, Langen KJ,
Scheffler B, Herrlinger U and Glas M: Dynamic
O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of
checkpoint inhibitor-related pseudoprogression in melanoma brain
metastases. Neuro Oncol. 18:1462–1464. 2016. View Article : Google Scholar
|
|
29
|
Ma Y, Wang Q, Dong Q, Zhan L and Zhang J:
How to differentiate pseudoprogression from true progression in
cancer patients treated with immunotherapy. Am J Cancer Res.
9:1546–1553. 2019.PubMed/NCBI
|
